This Plain Language Summary of Publication article (PLSP) from Future Oncology examined real-world effectiveness of palbociclib plus hormone therapy in patients with HR+/HER2- advanced breast cancer over up to 3 years of follow-up. Researchers assessed how well the treatment worked in routine clinical practice by measuring time without cancer progression, overall survival, and patient-reported quality of life outcomes.

Visit the site using this link to read the article.

This PLSP is based on two articles called:

‘Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer: final results from the POLARIS trial’ and was published in The Oncologist

‘Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS’ and was published in Breast Cancer Research and Treatment.

Visit Oxford Academic using the link to read the original article.

Visit Springer Nature using the link to read the original article.